Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with an unmet medical need, announces today the selection of the abstract “Lanifibranor, a pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH” retained for a plenary session presentation at the third International Conference on Fatty Liver to be held April 28-30, 2022 in Vienna, Austria.